Granzyme B in Autoimmune Skin Disease
department or school: Medicine, Faculty of
department or school: Pathology and Laboratory Medicine, Department of
data provider: DSpace
identifier citation: Biomolecules 13 (2): 388 (2023)
contributor: International Collaboration on Repair Discoveries
contributor: Vancouver Coastal Health Authority. Research Institute
creator: Gleave, Anna
creator: Granville, David James
issued: 2025-06-12T18:01:22Z
issued: 2023-02-18
description: Autoimmune diseases often present with cutaneous symptoms that contribute to dysfunction, disfigurement, and in many cases, reduced quality-of-life. Unfortunately, treatment options for many autoimmune skin diseases are limited. Local and systemic corticosteroids remain the current standard-of-care but are associated with significant adverse effects. Hence, there is an unmet need for novel therapies that block molecular drivers of disease in a local and/or targeted manner. Granzyme B (GzmB) is a serine protease with known cytotoxic activity and emerging extracellular functions, including the cleavage of cell–cell junctions, basement membranes, cell receptors, and other structural proteins. While minimal to absent in healthy skin, GzmB is markedly elevated in alopecia areata, interface dermatitis, pemphigoid disease, psoriasis, systemic sclerosis, and vitiligo. This review will discuss the role of GzmB in immunity, blistering, apoptosis, and barrier dysfunction in the context of autoimmune skin disease. GzmB plays a causal role in the development of pemphigoid disease and carries diagnostic and prognostic significance in cutaneous lupus erythematosus, vitiligo, and alopecia areata. Taken together, these data support GzmB as a promising therapeutic target for autoimmune skin diseases impacted by impaired barrier function, inflammation, and/or blistering.
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/91346
note: Citation: Gleave, A.; Granville, D.J.Granzyme B in Autoimmune SkinDisease. Biomolecules 2023, 13, 388.https://doi.org/10.3390/biom13020388Academic Editors: Ralf J. Ludwig,Takashi Hashimoto andRobert GniadeckiReceived: 6 January 2023Revised: 15 February 2023Accepted: 16 February 2023Published: 18 February 2023Copyright: © 2023 by the authors.Licensee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).biomoleculesReviewGranzyme B in Autoimmune Skin DiseaseAnna Gleave 1 and David J. Granville 1,2,*1 British Columbia Professional Firefighters’ Burn and Wound Healing Laboratory, International CollaborationOn Repair Discoveries (ICORD) Centre, Vancouver Coastal Health Research Institute, University of BritishColumbia, Vancouver, BC V5Z 1M9, Canada2 Department of Pathology and Laboratory Medicine, University of British Columbia,Vancouver, BC V6T 1Z7, Canada* Correspondence: dgranville@icord.orgAbstract: Autoimmune diseases often present with cutaneous symptoms that contribute to dysfunc-tion, disfigurement, and in many cases, reduced quality-of-life. Unfortunately, treatment options formany autoimmune skin diseases are limited. Local and systemic corticosteroids remain the currentstandard-of-care but are associated with significant adverse effects. Hence, there is an unmet need fornovel therapies that block molecular drivers of disease in a local and/or targeted manner. GranzymeB (GzmB) is a serine protease with known cytotoxic activity and emerging extracellular functions,including the cleavage of cell–cell junctions, basement membranes, cell receptors, and other structuralproteins. While minimal to absent in healthy skin, GzmB is markedly elevated in alopecia areata,interface dermatitis, pemphigoid disease, psoriasis, systemic sclerosis, and vitiligo. This review willdiscuss the role of GzmB in immunity, blistering, apopt…
has type: Article
is shown at: 10.14288/1.0449110
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: Multidisciplinary Digital Publishing Institute
publisher DOI: 10.3390/biom13020388
rights: CC BY 4.0
rights URI: https://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
scholar level: Researcher
subject: Granzyme B
subject: serine protease
subject: autoimmune skin disease
subject: inflammation
subject: extracellular matrix
subject: small molecule inhibitor
type: Text
identifier URI: http://hdl.handle.net/2429/91346